• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by NewGenIvf Group Limited

    11/13/24 9:19:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care
    Get the next $NIVF alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    NewGenIvf Group Limited

    (Name of Issuer)

     

    Class A Ordinary Shares, no par value per share

    (Title of Class of Securities)

     

    G0544E105

    (CUSIP Number)

     

    April 3, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. G0544E105 SCHEDULE 13G Page 2 of 8 Pages

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Chardan Capital Markets LLC

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☐

     

    3.  

    SEC USE ONLY

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    New York

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

      5.  

    SOLE VOTING POWER

     

    1,569,000*

      6.  

    SHARED VOTING POWER

     

    0

      7.  

    SOLE DISPOSITIVE POWER

     

    1,569,000*

      8.  

    SHARED DISPOSITIVE POWER

     

    0

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,569,000*

    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    15.5%*

    12.  

    TYPE OF REPORTING PERSON

     

    BD

     

    *See Item 4 for additional information.

     

     
     

     

    CUSIP No. G0544E105 SCHEDULE 13G Page 3 of 8 Pages

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Jonas Grossman

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☐

     

    3.  

    SEC USE ONLY

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

      5.  

    SOLE VOTING POWER

     

    1,569,000*

      6.  

    SHARED VOTING POWER

     

    0

      7.  

    SOLE DISPOSITIVE POWER

     

    1,569,000*

      8.  

    SHARED DISPOSITIVE POWER

     

    0

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,569,000*

    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    15.5%*

    12.  

    TYPE OF REPORTING PERSON

     

    IN

     

    *See Item 4 for additional information.

     

     
     

     

    CUSIP No. G0544E105 SCHEDULE 13G Page 4 of 8 Pages

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Steven Urbach

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐ (b) ☐

     

    3.  

    SEC USE ONLY

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

      5.  

    SOLE VOTING POWER

     

    1,569,000*

      6.  

    SHARED VOTING POWER

     

    0

      7.  

    SOLE DISPOSITIVE POWER

     

    1,569,000*

      8.  

    SHARED DISPOSITIVE POWER

     

    0

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,569,000*

    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    15.5%*

    12.  

    TYPE OF REPORTING PERSON

     

    IN

     

    *See Item 4 for additional information.

     

     
     

     

    CUSIP No. G0544E105 SCHEDULE 13G Page 5 of 8 Pages

     

    Item 1. Issuer.

     

      (a) Name of Issuer:

     

    NewGenIvf Group Limited (the “Issuer”).

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    13/F, PS Tower, Sukhumvit 21 RD (Asoke)

    Bangkok, Thailand, 0000

     

    Item 2. Filing Person.

     

      (a) - (c) Name of Persons Filing; Address; Citizenship:

     

    This Statement is being filed jointly on behalf of the following persons (collectively, the “Reporting Persons”):

     

    (i)Chardan Capital Markets LLC, a New York limited liability company (“CCM”);

     

    (ii)Mr. Steven Urbach (“Mr. Urbach”), a citizen of the United States of America, a manager of CCM; and

     

    (iii)Mr. Jonas Grossman (“Mr. Grossman”), a citizen of the United States of America, a manager of CCM.

     

    The principal business address of Mr. Grossman is 1 East Putman Avenue, 4th Floor, Greenwich, CT 06830. The principal business address of each of CCM and Mr. Urbach is One Pennsylvania Plaza, Suite 4800, New York, NY 10119.

     

      (d) Title of Class of Securities:

     

    Class A Ordinary Shares, no par value per share

     

      (e) CUSIP Number:

    .

    G0544E105

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

     
     

     

    CUSIP No. G0544E105 SCHEDULE 13G Page 6 of 8 Pages

     

    Item 4. Ownership.

     

    As reported in the cover pages to this report, the ownership information with respect to CCM is as follows:

     

    (a) Amount Beneficially Owned: 1,569,000*

     

    (b) Percent of Class: 15.5%*

     

    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 1,569,000*

     

    (ii) Shared power to vote or to direct the vote: 0

     

    (iii) Sole power to dispose or to direct the disposition of: 1,569,000*

     

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    As reported in the cover pages to this report, the ownership information with respect to Mr. Grossman is as follows:

     

    (a) Amount Beneficially Owned: 1,569,000*

     

    (b) Percent of Class: 15.5%*

     

    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 1,569,000*

     

    (ii) Shared power to vote or to direct the vote: 0

     

    (iii) Sole power to dispose or to direct the disposition of: 1,569,000*

     

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    As reported in the cover pages to this report, the ownership information with respect to Mr. Urbach is as follows:

     

    (a) Amount Beneficially Owned: 1,569,000*

     

    (b) Percent of Class: 15.5%*

     

    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 1,569,000*

     

    (ii) Shared power to vote or to direct the vote: 0

     

    (iii) Sole power to dispose or to direct the disposition of: 1,569,000*

     

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    *As of April 3, 2024, CCM held 1,569,000 Class A Ordinary Shares (the “Ordinary Shares”) of the Issuer. Each of Jonas Grossman and Steven Urbach, in their capacities as managers of CCM, has voting and investment discretion with respect to the Ordinary Shares held directly by CCM. As a result, each of Mr. Grossman and Mr. Urbach may be deemed to beneficially own the 1,569,000 Ordinary Shares held directly by CCM, representing approximately 15.5% of the outstanding Ordinary Shares as of April 3, 2024.

     

    Ownership percentages are based on an aggregate of 10,149,386 Ordinary Shares issued and outstanding on April 3, 2024, as reported in the Issuer’s Form 20-F filled with the Securities and Exchange Commission on April 9, 2024.

     

     
     

     

    CUSIP No. G0544E105 SCHEDULE 13G Page 7 of 8 Pages

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    CUSIP No. G0544E105 SCHEDULE 13G Page 8 of 9 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: November 13, 2024

     

      Chardan Capital Markets, LLC
         
      By: /s/ Steven Urbach
      Name: Steven Urbach
      Title: Manager
         
      By: /s/ Jonas Grossman
      Name: Jonas Grossman

     

      By: /s/ Steven Urbach
      Name: Steven Urbach

     

     

     

     

     

    Get the next $NIVF alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NIVF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NIVF
    SEC Filings

    View All

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    7/28/25 8:48:57 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    7/21/25 7:00:12 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    7/16/25 4:01:34 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NewGen Announces Strategic Acquisition of Cytometry Technology and Assets to Support Planned U.S. Expansion

    The new cytometry technology enhances accessibility, safety, and efficiency in sperm-sorting procedures The acquisition of 18 cell-sorting systems and associated patents positions NewGen for U.S. expansion, where over 430,000 IVF cycles took place in 2023 BANGKOK, July 29, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that it has acquired cytometry technology and assets including 18 fully-constructed cell-sorting and dispensing systems, eight partially constructed units, and six patents related to adva

    7/29/25 9:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Subsidiary Signs Memorandum of Understanding with Prominent UAE Real Estate Developer

    The agreement with BNW Real Estate Development LLC positions NewGenDigital to maximize the profitability of its recently acquired plot of land in the UAE Potential net return for the project is estimated to be as high as US$67 million per a feasibility study compiled by BNW BANGKOK, July 21, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that its subsidiary, NewGenDigital Limited ("NewGenDigital"), has signed a Memorandum of Understanding (the "MOU") with BNW Real Estate Development LLC ("BNW"), a prominent

    7/21/25 7:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Subsidiary Secures Strategic UAE Land and Begins Exploration of Potential Real World Asset Tokenization Initiative

    BANGKOK, July 01, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that its subsidiary, NewGenDigital Limited ("NewGenDigital"), has formally secured a strategic plot of land in Ras Al Khaimah's Beach District, UAE (the "Plot"), and is evaluating the feasibility of issuing digital tokens tied to the Plot as part of the Company's broader strategy to access blockchain-based asset digitization opportunities. This represents a significant milestone in the Company's previously announced US$45 million investment init

    7/1/25 7:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Chardan Capital Markets Llc claimed ownership of 1,569,000 units of Class A Ordinary Shares (SEC Form 3)

    3 - NewGenIvf Group Ltd (0001981662) (Issuer)

    11/13/24 9:16:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Leadership Updates

    Live Leadership Updates

    View All

    NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director

    Company Granted Request to Continue its Listing on NasdaqAppoints Thorain Ko to Lead Business Development Initiatives BANGKOK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to specific conditions. Additionally, the Company announced the appointment of Mr. Thorain Ko as Business Development Director to drive its expansion initiatives. Nasdaq Listing UpdateThe Pane

    2/20/25 6:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    12/5/24 8:23:57 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    11/13/24 9:19:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    10/10/24 3:39:26 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care